EUCTR2010-019841-25-IT进行中（未招募）不适用
A Phase II Study to evaluate activity and toxicity of Gemcitabine in Combination with Pemetrexed long term infusion in the Treatment of pretreated Metastatic Colorectal Cancer Patients
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.Histologic or cytologic confirmed diagnosis of colorectal carcinoma with metastatic (STAGE IV) disease. 2.Measurable disease according to RECIST criteria (see Appendix C). 3.Prior chemotherapy for metastatic disease is required; prior regimens (in adjuvant oral advanced stage setting) must include 5fluorouracile, Oxaliplatin and Irinotecan if not contraindicated.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 0
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 30
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 8
排除标准
- •1. Patients who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier. 2.Participation in another clinical trial with any investigational agents within 30 days prior to study screening. 3.Previous treatment with Gemcitabine or Pemetrexed. 4.History of allergic reactions attributed to compounds of similar chemical or biologic composition to Gemcitabine and/or Pemetrexed or other agents used in the study
研究者
相似试验
进行中（未招募）
不适用
Phase II study evaluating the toxicity and activity of the combination lapatinib + capecitabine in elderly patients aged 70 and over with metastatic breast cancer over expressing HER2ocally advanced or metastatic breast cancer over expressing HER2 and = 70 years oldMedDRA version: 12.0Level: LLTClassification code 10055113Term: Breast cancer metastaticMedDRA version: 12.0Level: LLTClassification code 10048406Term: Breast cancer aggravatedEUCTR2009-015981-73-FRFNCLCC (Fédération Nationale des Centres de Lutte Contre le Cancer)
招募中
2 期
To evaluate the impact of PET scan based radiotherapy planning for cervical cancer in Indian women.CTRI/2016/05/006924Department of Biotechnology Government of India60
已完成
2 期
5 Fraction Stereotactic Body Radiation Therapy for Oligometastases Regimen, for Extra-Cranial OligometastasesSolid Tumors With Oligometastatic SpreadNCT01761929University Health Network, Toronto138
进行中（未招募）
不适用
Etude de phase II d’évaluation de la toxicité et de l’efficacité d’un traitement par Tacrolimus (Prograf®) chez des patients atteints d’un lymphome diffus à grandes cellules B ou T. - LY-PROGRAPHymphomes malins diffus à grandes cellules B ou T.MedDRA version: 12.1Level: LLTClassification code 10025311Term: Lymphoma (non-Hodgkin's)EUCTR2009-017269-49-FRINSTITUT CURIE
尚未招募
2 期
To study the efficacy of a ayurvedic polyherbal preparation (Carctol-S) in patients with recurrent ovarian cancer.CTRI/2019/02/017873Central Council for Research in Ayurvedic Sciences Ministry of AYUSH Government of India